Table 3.
Association of survival outcomes and baseline CTC count.
| Overall Survival | |||
|---|---|---|---|
| Category | Median | HR (95%CI) | p-Value |
| <5 CTCs | 35.3 (28.4–NA) | 1 | 1 |
| 5–50 CTCs | 18.7 (15.9–24.3) | 2.69 (1.47–4.93) | 0.0014 |
| >50 CTCs | 8.4 (4.5–NA) | 40.4 (13.6–119.6) | <0.0001 |
| Progression-Free Survival (composite endpoint) | |||
| <5 CTCs | 9.9 (8.4–15.9) | 1 | 1 |
| 5–50 CTCs | 8.6 (7.4–10.7) | 1.66 (0.96–2.88) | 0.0691 |
| >50 CTCs | 2.9 (2.8–NA) | 8.13 (3.56–18.57) | <0.0001 |
| Time to PSA Progression | |||
| <5 CTCs | 8.3 (5.7–12.2) | 1 | 1 |
| 5–50 CTCs | 6.8 (5.8–7.7) | 1.96 (1.12–3.45) | 0.0187 |
| >50 CTCs | 3.7 (3–NA) | 5.35 (2.31–12.37) | 0.0001 |
Abbreviations: CTC, circulating tumor cell; PSA, prostate-specific antigen; NA, not available.